Alopecia areata is a common autoimmune disease, with a negative impact in health-related quality of life, especially when affecting children and adolescents. Current medical therapies, mainly for severe disease, are not effective. There are no FDA (Food and Drug Administration)- or ANVISA (Agência Nacional de Vigilância Sanitária)-approved therapy for children with alopecia areata. JAK inhibitors are emerging as a promising therapy.
Keywords: JAK inhibitors; adolescent; alopecia areata; dermatology; hair loss; tofacitinib.
© 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.